Axcelead DDP Collaborates with Astellas to Discover Candidates for Targeted Protein Degraders
Shots:
- Axcelead Drug Discovery Partners and Astellas have signed a drug discovery service agreement to identify new candidates for targeted protein degraders
- The alliance will leverage Axcelead DDP’s DegLead Platform for the discovery of these candidates
- Axcelead DDP’s DegLead Platform offers integrated solutions for targeted protein degrader discovery, including synthesis, compound libraries, high-throughput screening & profiling assays
Ref: BusinessWire | Image: Axcelead DDP & Astellas
Related News:- Astellas and Sangamo Therapeutics Partner for Administering Genomic Therapies Targeting Neurological Disorders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
